Početna › Akutna mijeloična leukemija › Minnesota
Kliničke studije za Akutna mijeloična leukemija u državi Minnesota
27 studija za Akutna mijeloična leukemija traži sudionike na lokacijama u državi Minnesota.
Gradovi u državi Minnesota
- Minneapolis20 studija
- Rochester12 studija
- Saint Paul6 studija
- Brooklyn Park6 studija
- Bloomington6 studija
- Duluth6 studija
Službeni tekst studije (engleski)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- i još 48
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- i još 8
U tijeku regrutacijaFaza 2
Od 18 do 59 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- i još 8
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- University of Minnesota/Masonic Cancer Center, Minneapolis
U tijeku regrutacijaFaza 1
Do 21 godina · Oba spola · Ažurirano 23. ruj 2026. · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- i još 8
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- i još 8
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- i još 9
U tijeku regrutacijaFaza 2
Od 18 do 59 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
U tijeku regrutacijaFaza 3
6 Months – 21 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT04293562Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT04588922Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Rochester MN-MAYOMN, Rochester
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
U tijeku regrutacijaFaza 1/2
Do 22 godina · Oba spola · Ažurirano 25. kol 2026. · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Masonic Cancer Center, Minneapolis
U tijeku regrutacijaFaza 3
29 Days – 21 Years · Oba spola · Ažurirano 24. kol 2026. · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Minnesota, Minneapolis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT07007312Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
- Masonic Cancer Center, Minneapolis
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 22. srp 2026. · NCT07008638HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
- Masonic Cancer Center, Minneapolis
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 14. srp 2026. · NCT06594445Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
U tijeku regrutacijaFaza 2
Do 75 godina · Oba spola · Ažurirano 6. srp 2026. · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
U tijeku regrutacijaFaza 2
Do 60 godina · Oba spola · Ažurirano 25. lip 2026. · NCT03314974A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. lip 2026. · NCT03017820Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
- Mark Juckett, MD, Minneapolis
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 19. svi 2026. · NCT07591649MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
U tijeku regrutacijaFaza 2
Od 2 do 75 godina · Oba spola · Ažurirano 16. tra 2026. · NCT07493538A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Mayo Clinic Comprehensive Cancer Center, Rochester
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 13. tra 2026. · NCT05732103Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
- University of Minnesota/Masonic Cancer Center, Minneapolis
U tijeku regrutacijaOpažajna studija
Do 25 godina · Oba spola · Ažurirano 8. tra 2026. · NCT05014165MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- University of Minnesota Masonic Cancer Center, Minneapolis
U tijeku regrutacijaFaza 2
Do 60 godina · Oba spola · Ažurirano 6. tra 2026. · NCT05735717Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
- Mayo Clinic in Rochester, Rochester
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 1. tra 2026. · NCT06279572A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Minnesota, Minneapolis
- Mayo Clinic - Rochester, Rochester
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. ožu 2026. · NCT05735184A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- Mayo Clinic, Rochester
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 9. velj 2026. · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Mayo Clinic, Rochester
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 120 godina · Oba spola · Ažurirano 25. srp 2025. · NCT05237258Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.